The benefit of adjuvant pertuzumab and trastuzumab according to estrogen receptor and HER2 expression: a Sub-analysis of the APHINITY trial.
AuteursAgostinetto E, Gentile G, Samy F, Di Cosimo S, Aftimos P, Pondé N, Eiger D, Lambertini M, Cameron D, Kiermaier A, Bailey A, Viale G, Loi S, Piccart M, de Azambuja E
Tafamidis in women with wild-type transthyretin cardiac amyloidosis: an international cohort study.
AuteursDebonnaire P, L'Hoyes W, Dujardin K, Donal E, Verheyen N, Dupont M, De Sutter J, Timmermans P, Pouleur AC, Droogmans S, Issa VS, Dulgheru R, Regeer M, Jurcut R, Bondue A, Bohyn A, Bogaerts K, Christiaen E, Wyseure N, Bezard M, Zach D, Schwegel N, Knapen R, Buytaert L, de Marneffe N, Ajmone Marsan N, Adam R, Tavernier R, Buysschaert I, Trenson S
Patient-reported outcomes and qualitative interviews in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the phase III EMBER-3 trial.
AuteursCurigliano G, O'Shaughnessy J, Bidard FC, Casalnuovo ML, Kim SB, Tokunaga E, Aftimos P, Saura C, Carey LA, Okera M, Melo E, Zagouri F, Magallanes-Maciel M, Karadurmus N, Bahadur S, Speck RM, Wang XA, Pradhan K, Macey J, Kitchen H, Fairhurst S, Miller J, Jhaveri KL, Harbeck N
